Dose-response to cytoskeletal-antigen specific immunoliposome therapy for preservation of myocardial viability and function in langendorff instrumented rat hearts.
Treatment with Cytoskeketal-antigen Specific ImmunoLiposomes (CSIL) has resulted in the preservation of cell and organ viability and function. The current study investigates whether CSIL-intervention is dose-dependent in Langendorff instrumented adult rat hearts undergoing global ischemia. Rat hearts undergoing experimental global ischemic insult for 25 minutes were treated with CSIL, IgG-liposomes (IgG-L), plain-liposomes (PL) or placebo. Infarct sizes were assessed by histochemical staining method and quantitated by computer planimetry. Mean infarct size of CSIL treated globally ischemic rat hearts was about 5 times smaller than that of control hearts (P <or= 0.02). Recovery to normal heart function was achieved with CSIL therapy at 1 mg antimyosin antibody dose, where as significant decreases in functional recovery were seen in hearts treated with 0.5 and 0.2 mg antimyosin antibody doses Dose-dependent preservation of cardiac function, and reduction in infarct sizes in CSIL treated hearts were concordant with ultrastructural evidence. Treatment of globally ischemic rat hearts with CSIL results in significant preservation of function and dramatic decrease in acute myocardial infarct size in a dose dependent process.